SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer. Available at: http://seer.cancer.gov/statfacts/html/kidrp.html. Accessed January 20, 2015.
Hutson TE, Lesovoy V, Al-Shukri S et al. . Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013;14:1287–1294.
Rini BI, Melichar B, Ueda T et al. . Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013;14:1233–1242.
Sternberg CN, Davis ID, Mardiak J et al. . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061–1068.
Hainsworth JD, Rubin MS, Arrowsmith ER et al. . Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium phase II trial. Clin Genitourin Cancer 2013;11:270–275.
Matrana MR, Duran C, Shetty A et al. . Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 2013;49:3169–3175.
Stewart SB, Thompson RH, Psutka SP et al. . Evaluation of the National Comprehensive Cancer Network and American Urological Association Renal Cell Carcinoma Surveillance guidelines. J Clin Oncol 2014;32:4059–4065.
Mucksavage P, Kutikov A, Magerfleisch L et al. . Comparison of radiographical imaging modalities for measuring the diameter of renal masses: is there a sizeable difference? BJU Int 2011;108:E232–236.
Gill IS, Kavoussi LR, Lane BR et al. . Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007;178:41–46.
Morgan WR, Zincke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol 1990;144:852–857.
Adamy A, Chong KT, Chade D et al. . Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 2011;185:433–438.